Page last updated: 2024-12-07

1-aminocyclobutanecarboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1-Aminocyclobutanecarboxylic acid (ACBCA)

1-Aminocyclobutanecarboxylic acid (ACBCA) is a **non-proteinogenic amino acid** with a unique cyclic structure. It consists of a cyclobutane ring with a carboxylic acid group and an amino group attached to it.

**Importance in Research:**

ACBCA has garnered interest in research due to its potential applications in various fields, including:

* **Biomedical Research:**
* **Drug Development:** ACBCA's unique structure can serve as a scaffold for developing novel drugs with improved properties, such as enhanced bioavailability, increased stability, or unique pharmacological activity.
* **Probing Protein Structure and Function:** ACBCA can be used as a probe for studying protein structure and function. Its unique properties allow it to bind to specific protein targets and can be used to map protein binding sites or study protein-ligand interactions.
* **Materials Science:**
* **Polymer Chemistry:** ACBCA can be incorporated into polymer chains to introduce specific functionalities, leading to new materials with unique properties, such as biodegradability or enhanced mechanical strength.
* **Agricultural Chemistry:**
* **Pesticide Development:** ACBCA can be utilized in the development of new pesticides with improved efficacy and reduced environmental impact.
* **Synthetic Chemistry:**
* **Organic Synthesis:** ACBCA serves as a versatile building block in organic synthesis, enabling the creation of complex molecules with diverse functionalities.

**Current Research:**

Currently, research on ACBCA focuses on:

* **Synthesis of ACBCA derivatives:** This involves exploring various synthetic routes to create diverse ACBCA analogs with different functionalities, potentially leading to novel drug candidates or building blocks for materials science.
* **Development of ACBCA-based biocompatible materials:** Research is ongoing to develop biocompatible polymers and materials incorporating ACBCA, offering applications in drug delivery, tissue engineering, and bioelectronics.
* **Exploring the biological activity of ACBCA:** Researchers are investigating the potential pharmacological effects of ACBCA and its derivatives, aiming to identify novel drug leads for treating various diseases.

**Overall, ACBCA's unique structure and diverse potential applications make it a promising molecule for future research across various disciplines, potentially leading to advancements in medicine, materials science, agriculture, and beyond.**

1-aminocyclobutanecarboxylic acid: RN given refers to unlabeled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID89643
CHEMBL ID131244
CHEBI ID190867
SCHEMBL ID61734
MeSH IDM0067412

Synonyms (73)

Synonym
AC-5714
bdbm50038160
DIVK1C_006749
nsc 403363
brn 2802253
cb 1700
1-aminocyclobutanecarboxlic acid
NCGC00024518-01
tocris-0258
nsc-403362
BSPBIO_002326
cyclobutanecarboxylic acid, 1-amino-
1-aminocyclobutanecarboxylic acid
nsc-403363
22264-50-2
nsc403363
1-amino-1-cyclobutanecarboxylic acid, 97%
1Y1Z
1-aminocyclobutane-1-carboxylic acid
KBIO3_001546
KBIO1_001693
KBIOGR_001312
SPECPLUS_000653
SPECTRUM2_001476
SPBIO_001431
SPECTRUM4_001046
SPECTRUM3_000743
SPECTRUM5_001835
NCGC00024518-02
STK330996
1-amino-cyclobutanecarboxylic acid
CHEMBL131244 ,
FT-0655686
FT-0657756
CHEBI:190867
1-aminocyclobutane carboxylic acid
A4782
BBL001782
1-aminocyclobutanecarboxylicacid
3-14-00-00843 (beilstein handbook reference)
unii-1k1pgc7j6z
1k1pgc7j6z ,
A816068
22264-16-0
CCG-39205
AKOS005172352
FT-0638207
1-amino-1-cyclobutanecarboxylic acid
AM20070607
PB32216
AB00053379-03
SCHEMBL61734
acbc
1-amino-1-cyclobutane carboxylic acid
J-504194
TS-01591
HB0100
DTXSID60176811
mfcd00661068
SR-01000597721-1
sr-01000597721
CS-D0209
HY-30006
117259-24-2
Q1147632
tert-butoxycarbonylamino-(4-tert-butoxycarbonylamino-phenyl)-aceticacid
1-amino-1-cyclobutanecarboxylicacid
SB10822
NCGC00024518-03
1-amino-1-cyclobutane carboxylic acid hydrochloride
EN300-93167
PD071292
SY002606

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" These data suggest that despite their brain bioavailability and marked potency at the glycine receptor in vitro, ACC and ACBC are rapidly inactivated and thus have limited in vivo utility."( Neuropharmacological characterization of 1-aminocyclopropane-1-carboxylate and 1-aminocyclobutane-1-carboxylate, ligands of the N-methyl-D-aspartate-associated glycine receptor.
Cler, JA; Compton, RP; Emmett, MR; Iyengar, S; Mick, S; Rao, TS; Sun, ET; Wood, PL, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
L-alpha-amino acidAny alpha-amino acid having L-configuration at the alpha-carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency79.43280.141337.9142100.0000AID1490
Microtubule-associated protein tauHomo sapiens (human)Potency12.58930.180013.557439.8107AID1460
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Glutamate [NMDA] receptor subunit zeta 1Rattus norvegicus (Norway rat)Ki831.00004.80005,378.600015,300.0000AID977610
Chain A, Glutamate [NMDA] receptor subunit zeta 1Rattus norvegicus (Norway rat)Ki831.00004.80005,378.600015,300.0000AID977610
Chain A, Glutamate [NMDA] receptor subunit zeta 1Rattus norvegicus (Norway rat)Ki831.00004.80005,378.600015,300.0000AID977610
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)19.00000.00071.600310.0000AID145260
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)19.00000.00071.630610.0000AID145260
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)19.00000.00061.525710.0000AID145260
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)18.75000.00071.747210.0000AID144708; AID145260
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)19.00000.00071.741110.0000AID145260
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)19.00000.00071.741110.0000AID145260
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)19.00000.00071.741110.0000AID145260
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2005Neuron, Jul-07, Volume: 47, Issue:1
Mechanism of partial agonist action at the NR1 subunit of NMDA receptors.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2005Neuron, Jul-07, Volume: 47, Issue:1
Mechanism of partial agonist action at the NR1 subunit of NMDA receptors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID144708Compound was evaluated for in vitro inhibition of oocytes at NMDA receptor.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID430782Displacement of [3H]glycine from strychnine-insensitive glycine recognition site of NMDA receptor in rat brain cortex membrane2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Drug design, in vitro pharmacology, and structure-activity relationships of 3-acylamino-2-aminopropionic acid derivatives, a novel class of partial agonists at the glycine site on the N-methyl-D-aspartate (NMDA) receptor complex.
AID430786Partial agonist activity at glycine site of NMDA receptor in rat brain cortex membrane assessed as potentiation of [3H]Mk-801 binding by liquid scintillation counting relative to glycine in presence of antagonist 5,7-dichlorokynurenic acid2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Drug design, in vitro pharmacology, and structure-activity relationships of 3-acylamino-2-aminopropionic acid derivatives, a novel class of partial agonists at the glycine site on the N-methyl-D-aspartate (NMDA) receptor complex.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID145260In vitro inhibition of [3H]glycine at NMDA receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (20.00)18.7374
1990's11 (44.00)18.2507
2000's3 (12.00)29.6817
2010's4 (16.00)24.3611
2020's2 (8.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.42 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]